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Abstract The objective of this study is to assess effects of
beta-blocker migraine prophylaxis on cortical excitability
determined by transcranial magnetic stimulation (TMS).
Phosphene and motor thresholds (PT, MT) were investi-
gated in 29 patients with migraine, in 15 of them prior to
and following preventive medication with metoprolol and
in 14 patients without prophylaxis. Following prophylaxis
headache frequency signiﬁcantly decreased (p = 0.005)
and mean PT were signiﬁcantly increased (51.5 ± 7.5 vs.
63.6 ± 8.4%) compared to patients without preventive
treatment (53.7 ± 5.3 vs. 52.3 ± 6.3%; p = 0.040). Mean
MT did not signiﬁcantly differ either between groups or due
to treatment. In the group of all patients, a signiﬁcant
inverse correlation between headache frequency and the
level of PT was found (R =- 0.629; p\0.01). There was,
however, no signiﬁcant correlation in the subgroups of
patients. We conclude that (a) clinical efﬁcacy of beta-
blocker treatment in migraine could be (at least partly)
linked to its ability to modulate the excitability of the visual
cortex and (b) the PT determined by TMS appears suitable
to assess the effects of prophylaxis on cortical excitability in
the individual patient. This may be useful in clinical trials
investigating migraine preventive drugs.
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Introduction
Migraine is one of the most frequent neurological disorders
and many patients require not only acute attack treatment
but also prophylactic medication. However, the exact
mechanisms of preventive anti-migraine treatment are still
unclear and may be multiple. Among various drugs with
different pharmacological properties used for prophylaxis
of migraine episodes, beta-blockers have been established
as highly effective agents. Propranolol and metoprolol are
well-documented substances, for review see [1, 2]. There is
increasing evidence in recent years that brainstem as well
as cortical dysfunction is basically involved in the complex
pathophysiology of migraine. Modiﬁed neuronal excit-
ability may be one explanation for preventive pharmaco-
logical effects. Electrophysiological and functional
imaging studies disclosed abnormalities of cortical infor-
mation processing [3–5] and of intracortical excitability
in migraine, predominantly within the visual cortex, for
review see [6]. As a common ﬁnding of altered cortical
excitability increased mean amplitudes of the contingent
negative variation (CNV) and lack of habituation of
amplitudes of visual evoked potentials in the interictal state
have been reported in migraine patients [7–12]. Normal-
ized amplitudes and habituation of evoked potentials fol-
lowing treatment with beta-blockers [13–15] and valproic
acid [16] provide some evidence that central neuronal
excitability changes in migraine patients due to prophy-
lactic medication.
As a different approach to explore noninvasively the
excitability of motor and visual cortical areas, transcranial
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patients with migraine. Findings on thresholds for eliciting
phosphenes (phosphene threshold, PT) in migraine patients
are controversial. Most studies reported decreased PT
suggesting a higher excitability of the visual cortex
between attacks [17–22], but opposite ﬁndings (increased
PT, reduced excitability) have been reported by some
authors [11, 23]. Using TMS an increase of mean PT in
migraine patients was found in few uncontrolled trials
following treatment with valproate [19], topiramate [24]
and levetiracetam [25].
The aim of the present study was to determine whether
motor and phosphene thresholds may change due to pre-
ventive treatment with the beta-blocker metoprolol in
patients with migraine with and without aura. To assess the
effect of treatment on cortical excitability, thresholds
before and after medication were compared with ﬁndings
in a group of non-treated migraine patients.
Methods
All patients were recruited from the headache outpatient
center of the neurological department of the University of
Duisburg-Essen. The study was approved by the local
ethics committee and informed consent was obtained from
all subjects.
Patients
Clinical characteristics of the patients are summarized in
Table 1. A total of 29 right-handed outpatients who met the
criteria for migraine [26] and who were free from any
preventive medication during the last 6 months were
investigated. Patients were allowed to use acute headache
medication. Inclusion criteria were migraine with aura
(MwA) or without aura (MwoA), age 18–65 years and
duration of illness [6 months. Patients with chronic
migraine or overuse of analgetics and other acute migraine
or pain medication were excluded from the study. Further
exclusion criteria were epilepsy, pregnancy, mental disor-
der or substance abuse. The preventively treated group
consisted of unselected patients with current migraine
attacks of at least two per month. In these15 patients
(2 male, 13 female; 6 with MwA, 9 with MwoA; mean
attack frequency 3.33 ± 0.97 per month; mean age 37.3 ±
11.5 years, range 18–60 years; mean disease duration
15.3 ± 12.9 years) preventive migraine therapy with
metoprolol was initiated by the headache outpatient center.
The patients were compared with a group of migraine
patients who did not receive preventive treatment by the
headache outpatient center consisting of 14 age- and sex-
matched patients with lower headache frequencies up to
two per month (2 male, 12 female; 7 with MwA, 7 with
MwoA; mean attack frequency 1.43 ± 0.90 per month;
mean age 37.4 ± 13.8 years, range 21–64 years; mean
disease duration 12.2 ± 8.9 years).
Study design
Metoprolol was started with 25 mg per day and increased
by 25–50 mg per week up to the target dosage of 100 mg
per day, which was continued for 8 weeks. In each patient
aheadachediarywasusedtoassessheadachefrequencyat
baseline and on follow-up evaluation. All electrophysio-
logical studies were performed at least 3 days before or
after a migraine attack or acute migraine treatment. This
was conﬁrmed by a phone call 1 week after the examina-
tion. In female patients the time of measurement was
distributed randomly throughout both phases of the men-
strual cycle. Moreover, the anti-migraine drugs and doses
taken for attack treatment were recorded. Headache fre-
quency (number of attacks per month) at baseline was
calculated within the last 6 months retrospectively.
Baseline measurements were done before start of the
prophylacticmedicationinpatientsofthetreatmentgroup.
Thefollow-upevaluationwasperformed8 weeksafterthe
startoftreatment.InthesamemannerTMSmeasurements
were performed twice in patients without preventive
medication.
Magnetic stimulation
TMS procedures have been described in detail previously
[22] and are repeated brieﬂy. TMS was performed using a
Medtronic Dantec MagPro stimulator (Dantec, Skovlunde,
Denmark) and an eight-shaped coil (2 9 10 coil windings,
outer diameter 10 cm) and by one investigator (M. G.) who
was blinded to the treatment status of the patients.
Table 1 Clinical characteristics of migraine patients
Clinical
characteristics
Patients treated
with beta-blocker
Patients without
prophylaxis
N 15 14
MwA/MwoA 6/9 7/7
Male/female 2/13 2/12
Mean age (years) 37.3 ± 11.5 37.4 ± 13.8
Age range (years) 18–60 21–64
Mean disease
duration (years)
15.3 ± 12.9 12.2 ± 8.9
Mean attack
frequency/month
3.33 ± 0.97 1.43 ± 0.90
Group mean values are expressed ± standard deviation (SD)
MwA migraine with aura, MwoA migraine without aura
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Motor thresholds were determined while the coil was
placed over the hand associated primary motor cortex of
the right hemisphere, the handle was directed posteriorly.
First, stimuli were applied with suprathreshold intensity
and the coil was moved in steps of 1 cm to determine the
optimal scalp position for producing motor evoked poten-
tials (MEP) of maximal amplitude (lowest threshold) in the
contralateral target hand muscle. Stimulus intensities then
were reduced in steps of 2% of maximal stimulator output.
MEP were recorded with bipolar surface electrodes
attached over the ﬁrst dorsal interosseus muscle. The
electromyographic signals were ampliﬁed with band pass
ﬁltering between 20 Hz and 3 kHz and recorded with a
personal computer using an analogue digital converter
(CED 1401 plus Interface, recording frequency 5,000/sec
per channel) and a data registration program (SigAvg;
CED, Cambridge, UK). Threshold for eliciting MEP was
deﬁned as the lowest stimulus intensity (% of maximal
stimulator output) capable of eliciting at least ﬁve MEP
with an amplitude of at least 100 lV in a relaxed hand
muscle in a series of ten consecutive trials of TMS [27].
Phosphene threshold
For elicitation of phosphenes the coil was centered over the
occipital skull with the handgrip pointing horizontally into
lateral direction [28]. The MagPro stimulator provides
pulses (biphasic pulses; duration: 340 ls) with identical
stimulus intensities through the same coil. The subjects
were blindfolded and wore a swimmer cap with a surface
grid system of 1 9 1 cm intersections parallel to the
medio-sagittal line and the interaural line. This was used to
enable the exact repositioning of the coil.
The subjects were asked to report every bright or col-
ored visual perception during TMS. Due to a previous
methodological paper the stimulation procedure started
with suprathreshold TMS pulses over the right visual cor-
tex to provide an experience of phosphene perception to the
subjects [29]. The coil was moved in steps of 1 cm in
mediolateral and craniocaudal direction to identify the
optimal position in which brief ﬂashes or white patches of
light were consistently reported foveally or within the left
visual hemiﬁeld. At this point, phosphene thresholds were
determined in each subject. For this purpose TMS was
initially applied with a stimulus intensity of 20% of maxi-
mal stimulator output and further increased in steps of 5%
until phosphenes were reported. Then, the threshold was
ﬁne-tuned by varying the stimulus intensity in steps of 2%.
To avoid order effects, we randomized the direction
(increasing/decreasing) in which the stimulus intensity was
changed. PT was deﬁned as the minimal stimulus intensity,
at which the subjects reported phosphenes in at least ﬁve
out of ten stimulations at a given coil position. The inter-
trial intervals were at least 10 s. To avoid changes of visual
cortex excitability due to a prolonged sensory deprivation,
the examination was interrupted every 10–15 min and light
exposure was provided to the subjects [30].
Data analysis
SPSS software (Version 14.0) was used for statistical
evaluation. Analysis of variance with repeated measures
(ANOVA) was performed to compare PT and MT as well
as migraine frequency between the ﬁrst and second
assessment, i.e. time as within subject factor and groups
that is prophylactic treatment versus no treatment as
between subjects factor and to calculate the effect of
treatment on thresholds (interaction effect). Level of sig-
niﬁcance with p\0.05 was accepted. Statistical evalua-
tion of headache frequency was based on time series
analysis of variance of groups, i.e. preventively treated
patients and non-treated patients. Response to treatment
was deﬁned as reduction of at least 50% of migraine epi-
sodes per month. The Spearman Pearson Product Moment
Correlation coefﬁcient was used to analyze the relation
between headache frequency and PT and changes of
headache frequency and PT in migraine patients with and
without preventive treatment.
Results
Clinical efﬁcacy
Comparingtheindividualdifferencesofheadachefrequencies
at the ﬁrst and second testing, in 11 out of the 15 treated
patients (73.3%) migraine episodes were reduced C50%
at second testing. The mean frequency of migraine attacks
signiﬁcantly decreased following beta-blocker treatment
(3.33 ± 0.97 vs. 1.47 ± 1.26 per month), but was lower and
remained nearly unchanged in patients without prophylaxis
(1.43 ± 0.90 vs. 1.30 ± 0.73 per month). Comparison of
change of headache frequencies between groups showed
signiﬁcant time (F1,27 = 32.6; p\0.001) and time by group
effects (F1,27 = 24.8; p\0.001), the group effect was also
signiﬁcant (F1,27 = 9.5; p = 0.005).
Motor thresholds
MT ranged from 30 to 48% of maximal stimulator output
in treated and from 32 to 55% in the non-treated group.
Comparison of mean MT at baseline and follow up
between groups (38.0 ± 5.8 vs. 38.9 ± 4.4% in treated and
39.3 ± 5.9 vs. 40.7 ± 6.1% in non-treated patients) did not
J Headache Pain (2012) 13:83–89 85
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p[0.5), also the group effect (F1,27 = 0.56; p = 0.45)
was not signiﬁcant.
Phosphene thresholds
Following occipital stimulation phosphenes were reported
by all subjects, located foveally or within the lower
quadrants of the visual ﬁeld. Optimal stimulation sites to
elicit phosphenes lay 1–5 cm above the inion. There were
no adverse effects related to TMS in any of the partici-
pants. Individual phosphene thresholds determined by
single-pulse magnetic stimulation are shown in each sub-
ject with and without preventive treatment at baseline and
follow-up measurement (Fig. 1). At second testing
thresholds were enhanced in 14 of the treated patients.
However, in the 11 patients who clinically responded to
treatment PT increase ranged from 4 to 23% of maximum
stimulator output, in one subject PT was slightly decreased
following treatment. Conversely, in two of the four non-
responding patients PT were enhanced at second testing.
This was the case in three of the non-treated patients, in
ﬁve of them thresholds were decreased at second testing.
Mean PT was not different between groups at baseline, but
was increased following preventive treatment in contrast to
the non-treated patients (51.5 ± 7.5 vs. 63.6 ± 8.4% and
53.7 ± 5.3 vs. 52.3 ± 6.3%; Fig. 2). ANOVA with repe-
ated measures with PT as dependent variable, time as
within subjects factor and treatment status as between
subjects factor revealed a signiﬁcant time by group effect
(F1,27 = 27.9; p\0.001) and a signiﬁcant group effect
(F1,27 = 4.7; p = 0.040) indicating that mean PT were sig-
niﬁcantly enhanced following treatment. No signiﬁcant dif-
ference was found comparing mean PT at baseline and PT
enhancement in MwA-and MwoA-patients of the treated
group. In the group of all subjects headache frequency was
inversely and signiﬁcantly correlated with the level of PT
(R =- 0.629, p\0.01; Fig. 3a). Correlation was not signiﬁ-
cant in subgroups of patients either in treated patients (R =
-0.220,p = 0.43)orinthenon-treatedpatients(R =- 0.491,
p = 0.075).Furthermore,analysisofPTchangeversusclinical
change did not reveal any signiﬁcant correlation either in
patientsrespondingtotreatment(R =- 0.70,p = 0.837)orin
non-responders (R = 0.219, p = 0.781).
Discussion
In patients of the present study the frequency of migraine
attacks was inversely correlated with the level of phos-
phene thresholds. In a subgroup of patients, treatment with
metoprolol resulted in a reduction of mean attack fre-
quency and an increase of mean PT to a level observed
previously in a group of healthy controls [22]. In these
patients the headache frequency was higher than in a
control group of patients without migraine prophylaxis.
The ﬁndings suggest that preventive treatment with a beta-
blocker in migraine may reduce the excitability of the
Fig. 1 Individual phosphene thresholds (% of the maximal stimulator
output) in migraine patients determined by single-pulse TMS at
baseline and following beta-blocker treatment (a) and in patients
without preventive treatment (b)
Fig. 2 Mean phosphene thresholds ± SE at baseline (dark blue
columns) and follow-up (light blue columns) in preventively treated
patients compared to patients without migraine prophylaxis
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123visual cortex. However, clinical efﬁcacy was not signiﬁ-
cantly correlated with enhancement of mean PT.
The signiﬁcant decrease of headache frequency in the
present patients following treatment is consistent with the
good evidence of effective migraine prevention by beta-
blocking agents [31–33]. The underlying mechanisms of the
prophylactic efﬁcacy of substances used in migraine pre-
vention are a matter of ongoing discussion. One explanation
centers on a modiﬁed central neuronal excitability due to
treatment. This is supported by the present ﬁndings of
enhanced mean PT following prophylactic medication.
Comparable to the corticomotor threshold, phosphene
thresholds have been shown to represent a reliable param-
eter of visual cortex excitability in healthy subjects and to
be stable across repeated measurements [34–36]. Mean PT
remained unchanged in the present patients without pre-
ventive treatment. Interestingly, values tended to be lower
at second testing possibly because the subjects were more
experienced in the recognition of phosphenes.
In recent years many studies investigated electrophysi-
ological parameters in migraine [6]. Following beta-
blocker treatment altered amplitudes and habituation of the
contingent negative variation [13, 37] as well as amplitudes
and latencies of pattern reversal visual evoked potentials
[14] were reported to normalize. Also in the present
patients mean PT increased to values corresponding to that
in healthy controls as assessed in a previous trial. Consis-
tent with earlier ﬁndings the data suggest that modiﬁed
central excitability may be one factor of prophylactic
efﬁcacy of beta-blocker treatment in migraine and that
dysfunction of cortical excitability is at least associated
with mechanisms underlying the pathophysiology of
migraine.
However, lack of signiﬁcant correlation of PT
enhancement with clinical improvement shows that PT
related changes of cortical excitability do not appear to
predict per se preventive efﬁcacy. This is supported by
ﬁndings in individual patients. Two out of four patients,
although not responding to treatment, showed higher PT at
second testing. Conversely, single patients out of the
clinical responders showed only slight or no increase of PT
following treatment. Although most migraineurs may be
characterized by modiﬁed cortical excitability, it therefore
cannot be deﬁnitely assessed that it is one of the causes of
the disease and not just an epiphenomenon strictly linked to
the disease. Moreover, as clinical response may represent a
placebo (in common clinical trials about 30%) rather than a
biological effect, attribution of the clinical efﬁcacy to the
treatment or PT change on a case-by-case basis remains
uncertain.
The current data are consistent with a previous, uncon-
trolled study using valproate, also known to be effective in
migraine prevention [19]. Following medication ascent of
low mean PT was observed, however, only in MwA
patients and correlation of PT enhancement with clinical
efﬁcacy tended to signiﬁcance. Two further uncontrolled
TMS studies were conducted using other antiepileptic
drugs for migraine prophylaxis. In an open label trial with
levetiracetam change of headache frequency and change of
PT were negatively correlated at the 10% but not at the 5%
signiﬁcance level [25]. Mean PT were also increased fol-
lowing preventive treatment with topiramate in patients
with migraine without aura [24]. Surprisingly, an inverse
correlation was reported between decrease of migraine
frequency and increase of mean PT. In the present study,
however, no signiﬁcant difference of mean PT at baseline
and PT enhancement due to treatment was observed com-
paring MwA- and MwoA-patients. Findings of previous
studies and the present data suggest that migraine pro-
phylaxis with different centrally acting substances may be
more complex and cannot only be explained by modiﬁca-
tion of cortical excitability. A non-linear relation between
migraine activity and PT in patients with frequent migraine
has also been discussed [24].
Fig. 3 Correlation between changes of attack frequencies per month and differences of phosphene thresholds in all patients (a), patients without
migraine prophylaxis (b) and patients with beta-blocker treatment (c). Note that several dots in (a) and (b) represent two or more subjects
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of cortical spreading depression in migraine pathophysi-
ology. In rats it has been shown that chronic treatment with
different migraine prophylactic drugs suppresses cortical
spreading depression in a duration-dependent manner and
increases the electrical stimulation threshold [38]. Since
increased central noradrenergic activity may be a basic
phenomenon in the pathophysiology of migraine, ﬁndings
of the present and earlier studies following beta-blocker
treatment suggest that one mechanism of migraine pro-
phylaxis may be to act on cortical hyperexcitability.
In the present patients mean MT did not change due to
preventive treatment. Studies evaluating MT over the pri-
mary motor cortex in patients with migraine revealed
controversial results [11, 39–41], no signiﬁcant changes of
MT in migraine were reported more recently [34, 42].
Following treatment with topiramate mean MT was
enhanced, again there was no correlation with clinical
effects [24]. However, even if report of excitability dys-
function in migraine are controversial concerning the MT
assessment, motor cortex plasticity has been found to be
consistently altered (short term plasticity and homeostatic
plasticity) in the direction of increased responsivity in
migraine [43, 44]. Indeed changes in plasticity more than
pure hyper- or hypoexcitability are likely more speciﬁc for
migraine pathophysiology [43, 44]. Moreover, modulation
of such mechanisms by migraine prophylaxis has been
shown in the visual and motor cortex [43–45].
In conclusion the present ﬁndings suggest that effects of
beta-blockers in migraine prevention are, at least in part,
related to inﬂuences on the excitability of the visual cortex.
Due to treatment decreased mean PT were restored to a
level corresponding to that in healthy controls as shown in
a previous study. This was not observed in all subjects who
responded to treatment suggesting that phosphene thresh-
olds elicited by occipital TMS appear suitable to measure
effects of prophylaxis on cortical excitability only in
individual patients.
There are several limitations of the study. The baseline
PT tests gave similar results in both groups, who were
different for headache frequency. It might be useful to
investigate patients with comparable attack frequencies at
baseline. Moreover, there was a higher responder rate
compared to clinical trials which may be due to the rela-
tively small sample size and may therefore not reﬂect data
of larger clinical trials. Finally, the design was not ran-
domized and there was no placebo control.
Lack of signiﬁcant correlation in treated patients of the
present study, however, suggests that clinical efﬁcacy of
migraine prevention may in addition depend on effects
distinct from cortical excitability [24]. Imaging studies
have shown that the rostral brainstem may enhance cortical
activation in migraine [46, 47] and effects of migraine
preventive drugs on other brain structures are likely. Fur-
ther studies with larger groups of patients are needed to
evaluate whether and to what extent clinical effects of
substances used in migraine prevention may be related to
cortical excitability and to determine long lasting effects.
Conﬂict of interest Prof. Dr. Hans-Christoph Diener received
honoraria for participation in clinical trials, contribution to advisory
boards or oral presentations from: Addex Pharma, Allergan, Almirall,
AstraZeneca, Bayer Vital, Berlin Chemie, Bo ¨hringer Ingelheim,
Bristol-Myers Squibb, Coherex, CoLucid, GlaxoSmithKline, Gru ¨-
nenthal, Janssen-Cilag, Lilly, La Roche, 3M Medica, Medtronic,
Menerini, Minster, MSD, Neuroscore, Novartis, Johnson & Johnson,
Pierre Fabre, Pﬁzer, Schaper and Bru ¨mmer, Sanoﬁ, St. Jude and
Weber & Weber. Financial support for research projects was provided
by Allergan, Almirall, AstraZeneca, Bayer, GSK, Janssen-Cilag,
MSD and Pﬁzer. Headache research at the Department of Neurology
in Essen is supported by the German Research Council (DFG), the
German Ministry of Education and Research (BMBF) and the Euro-
pean Union. H.C. Diener has no ownership interest and does not own
stocks of any pharmaceutical company.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution and reproduction in any medium, provided the original
author(s) and source are credited.
References
1. Diener H, Limmroth V (2004) Prevention of migraine: betab-
lockers and amine agonists efﬁcacy. In: Olesen J, Silberstein S,
Tfelt-Hansen P (eds) Preventive pharmacotherapy of headache
disorders. Oxford University Press, Oxford, pp 59–66
2. Silberstein SD (2009) Preventive migraine treatment. Neurol Clin
27:429–443
3. Kropp P, Gerber WD (1995) Contingent negative variation during
migraine attack and interval: evidence for normalization of slow
cortical potentials during the attack. Cephalalgia 15:123–128
4. Schoenen J (2009) Abnormal cortical information processing
between migraine attacks. In: Sandler M, Ferrari M, Harnett S
(eds) Migraine: pharmacology and genetics. Altman, London,
pp 233–253
5. Vincent M, Pedra E, Mourao-Miranda J, Bramati IE, Henrique
AR, Moll J (2003) Enhanced interictal responsiveness of the
migraineous visual cortex to incongruent bar stimulation: a
functional MRI visual activation study. Cephalalgia 23:860–868
6. Schoenen J, Ambrosini A, Sandor PS, Maertens de Noordhout A
(2003) Evoked potentials and transcranial magnetic stimulation
in migraine: published data and viewpoint on their pathophysi-
ologic signiﬁcance. Clin Neurophysiol 114:955–972
7. Schoenen J, Maertens A, Timsit-Berthier M, Timsit M (1985)
Contingent negative variation (CNV) as a diagnostic and physio-
pathologic tool in headache patients. In: Rose FC (ed) Migraine.
Clinical and research advances. Karger, Basel, pp 17–25
8. Schoenen J, Timsit-Berthier M, Timsit M (1985) Correlations
between contingent negative variation and plasma levels of cat-
echolamines in headache patients. Cephalalgia 5(Suppl 1):480
9. Schoenen J, Wang W, Albert A, Delwaide PJ (1995) Potentiation
instead of habituation characterizes visual evoked potentials in
migraine patients between attacks. Eur J Neurol 2:115–122
10. Kropp P, Gerber WD (1993) Contingent negative variation-
ﬁndings and perspectives in migraine. Cephalalgia 13:33–36
88 J Headache Pain (2012) 13:83–89
12311. Afra J, Mascia A, Ge ´rard P, Maertens de Noordhout A, Schoenen
J (1998) Interictal cortical excitability in migraine. A study using
transcranial magnetic stimulation of motor and visual cortices.
Ann Neurol 44:209–215
12. Wang W, Wang YH, Fu XM, Sun ZM, Schoenen J (1999)
Auditory evoked potentials and multiple personality measures in
migraine and post-traumatic headaches. Pain 79:235–242
13. Schoenen J, Maertens de Noordhout A, Timsit-Berthier M, Timsit
M (1986) Contingent negative variation and efﬁcacy of beta-
blocking agents in migraine. Cephalalgia 6:229–233
14. Diener HC, Scholz E, Dichgans J, Gerber WD, Jack A, Bille A,
Niederberger U (1989) Central effects of drugs used in migraine
prophylaxis evaluated by visual evoked potentials. Ann Neurol
25:125–130
15. Sa ´ndor PS, Afra J, Ambrosini A, Schoenen J (2000) Prophylactic
treatment of migraine with beta-blockers and riboﬂavin: differ-
ential effects on the intensity dependence of auditory evoked
cortical potentials. Headache 40:30–35
16. Schoenen J (1997) Clinical neurophysiology of headache. Neurol
Clin 15:85–105
17. AuroraSK,AhmadBK,WelchKMA,BhardhwajP,RamadanNM
(1998) Transcranial magnetic stimulation conﬁrms hyperexcit-
ability of occipital cortex in migraine. Neurology 50:1111–1114
18. Aurora SK, Welch KM, Al-Sayed F (2003) The threshold for
phosphenes is lower in migraine. Cephalalgia 23:258–263
19. Mulleners WM, Chronicle EP, Palmer JE, Koehler PJ, Vredeveld
JW (2001) Visual cortex excitability in migraine with and with-
out aura. Headache 41:565–572
20. Battelli L, Black KR, Wray SH (2002) Transcranial magnetic
stimulationofvisualareaV5inmigraine.Neurology58:1066–1069
21. Young WB, Oshinsky ML, Shechter AL, Gebeline-Myers C,
Bradley KC, Wassermann EM (2004) Consecutive transcranial
magnetic stimulation: phosphene thresholds in migraineurs and
controls. Headache 44:131–135
22. Gerwig M, Niehaus L, Kastrup O, Stude P, Diener HC (2005)
Visual cortex excitability in migraine evaluated by single and
paired magnetic stimuli. Headache 45:1394–1399
23. Bohotin V, Fumal A, Vandenheede M, Bohotin C, Schoenen J
(2003) Excitability of visual V1–V2 and motor cortices to single
transcranial magnetic stimuli in migraine: a reappraisal using a
ﬁgure-of-eight coil. Cephalalgia 23:264–270
24. Artemenko AR, Kurenkov AL, Filatova EG, Nikitin SS, Kaube
H, Katsarava Z (2008) Effects of topiramate on migraine fre-
quency and cortical excitability in patients with frequent
migraine. Cephalalgia 28:203–208
25. Young W, Shaw J, Bloom M, Gebeline-Myers C (2008) Corre-
lation of increase in phosphene threshold with reduction of
migraine frequency: observation of levetiracetam-treated sub-
jects. Headache 48:1490–1498
26. International Headache Society (2004) The international classi-
ﬁcation of headache disorders, 2nd edn. Cephalalgia 24(Suppl 1):
9–160
27. Rossini PM, Barker AT, Berardelli A (1994) Non-invasive
electrical and magnetic stimulation of the brain, spinal cord and
roots: basic principles and procedures for routine clinical appli-
cation. Report of an IFCN committee. Electroencephalogr Clin
Neurophysiol 91:79–92
28. Kammer T, Beck S, Erb M, Grodd W (2001) The inﬂuence of
current direction on phosphene thresholds evoked by transcranial
magnetic stimulation. Clin Neurophysiol 112:2015–2021
29. Gerwig M, Kastrup O, Meyer BU, Niehaus L (2003) Evaluation
of cortical excitability by motor and phosphene thresholds in
transcranial magnetic stimulation. J Neurol Sci 215:75–78
30. Boroojerdi B, Bushara KO, Corwell B, Immisch I, Battaglia F,
Muellbacher W, Cohen LG (2000) Enhanced excitability of the
human visual cortex induced by short-term light deprivation.
Cereb Cortex 10:529–534
31. Holroyd KA, Penzien DB, Cordingley GE (1991) Propranolol in
the management of recurrent migraine: a meta-analytic review.
Headache 31:333–340
32. Linde K, Rossnagel K (2004) Propranolol for migraine prophy-
laxis. Cochrane Database Syst Rev (2):CD003225
33. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sa ´ndor
PS (2009) European Federation of Neurological Societies. EFNS
guideline on the drug treatment of migraine–revised report of an
EFNS task force. Eur J Neurol 16:968–981
34. Amassian VE, Cracco RQ, Maccabee PJ, Cracco JB, Rudell A,
Eberle L (1998) Transcranial magnetic stimulation in study of the
visual pathway. J Clin Neurophysiol 15:288–304
35. Stewart LM, Walsh V, Rothwell JC (2001) Motor and phosphene
thresholds: a transcranial magnetic stimulation correlation study.
Neuropsychologia 39:415–419
36. Boroojerdi B, Meister IG, Foltys H, Sparing R, Cohen LG,
To ¨pper R (2002) Visual and motor cortex excitability: a trans-
cranial magnetic stimulation study. Clin Neurophysiol 113:1501–
1504
37. Maertens de Noordhout A, Timsit-Berthier M, Timsit M,
Schoenen J (1987) Effects of beta blockade on contingent neg-
ative variation in migraine. Ann Neurol 21:111–112
38. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA (2006)
Suppression of cortical spreading depression in migraine pro-
phylaxis. Ann Neurol 59:652–661
39. Bettucci D, Cantello R, Gianelli M, Naldi P, Mutani R (1992)
Menstrual migraine without aura: cortical excitability to magnetic
stimulation. Headache 32:345–347
40. Maertens de Noordhout A, Pepin JL, Schoenen J, Delwaide PJ
(1992) Percutaneous magnetic stimulation of the motor cortex in
migraine. Electroencephalogr Clin Neurophysiol 85:110–115
41. van der Kamp W, Maassen VanDenBrink A, Ferrari MD, van
Dijk JG (1996) Interictal cortical hyperexcitability in migraine
patients demonstrated with transcranial magnetic stimulation.
J Neurol Sci 139:106–110
42. Brighina F, Piazza A, Daniele O, Fierro B (2002) Modulation of
visual cortical excitability in migraine with aura: effects of 1 Hz
repetitive transcranial magnetic stimulation. Exp Brain Res
145:177–181
43. Brighina F, Cosentino G, Vigneri S, Talamanca S, Palermo A,
Giglia G, Fierro B (2011) Abnormal facilitatory mechanisms in
motor cortex of migraine with aura. Eur J Pain 15 (9):928–935
[Epub ahead of print]
44. Conte A, Barbanti P, Frasca V, Iacovelli E, Gabriele M, Gia-
comelli E, Aurilia C, Pichiorri F, Gilio F, Inghilleri M (2010)
Differences in short-term primary motor cortex synaptic poten-
tiation as assessed by repetitive transcranial magnetic stimulation
in migraine patients with and without aura. Pain 148:43–48
45. Palermo A, Fierro B, Giglia G, Cosentino G, Puma AR, Brighina
F (2009) Modulation of visual cortex excitability in migraine
with aura: effects of valproate therapy. Neurosci Lett 467:26–29
46. Weiller C, May A, Limmroth V, Ju ¨ptner M, Kaube H, Schayck
RV et al (1995) Brain stem activation in spontaneous human
migraine attacks. Nat Med 1:658–660
47. Goadsby PJ (2002) Neurovascular headache and a midbrain
vascular malformation: evidence for a role of the brainstem in
chronic migraine. Cephalalgia 22:107–111
J Headache Pain (2012) 13:83–89 89
123